At the 2023 ASCO Annual meeting, the latest information on the Japan Phase II study of Nanvuranlat (development code: JPH203) will be announced. Nanvuranlat is a novel L-type amino acid transporter 1 (LAT1) inhibitor for refractory biliary tract cancer patients

April 27, 2023
J-Pharma Co., Ltd.

J-Pharma Co., Ltd. (Headquarters: Yokohama, Kanagawa; President & CEO: Max Yoshitake).

Nanvuranlat is a novel low-molecular-weight compound that J-Pharma has independently created targeting L-type amino acid transporter 1 (LAT1). The latest information on the Japan Phase II trial of “Nanvuranlat (development code: JPH203)” for advanced refractory biliary tract cancer will be announced from the 2nd to 6th June 2023, in Chicago, Illinois, USA. Additional updates will be presented at the 2023 ASCO Annual Meeting.

１． Session Type/Title:
Clinical Science Symposium – Target or TIGIT in Hepatobiliary Cancer

２． Session Date and Time:
June 4, 2023 4:30 PM-6:00 PM（U.S. CDT）

３． Location:
Arie Crown Theater

４． Abstract Number for Publication:
4011

５． Abstract Title:
Subgroup analysis of double-blind, placebo-controlled Ph. 2 study of nanvuranlat in treatment of pre-treated, advanced, refractory biliary tract cancer (BTC): Patients with high LAT1 expression and response to nanvuranlat.

６． Presenter: (Oral presentation)
Masafumi Ikeda, MD, PhD | Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East